Literature DB >> 24060077

[Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version].

Xu-chao Zhang1, Shun Lu, Li Zhang, Chang-li Wang, Ying Cheng, Gan-di Li, Tony Mok, Cheng Huang, Xiao-qing Liu, Jie Wang, Meng-zhao Wang, Yi-ping Zhang, Jian-ying Zhou, Xiao-yan Zhou, Dong-mei Lin, Jin-ji Yang, Hui Li, Hai-quan Chen, Wen-zhao Zhong, Yi-long Wu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24060077     DOI： 10.3760/cma.j.issn.0529-5807.2013.06.012

Source DB:  PubMed          Journal:  Zhonghua Bing Li Xue Za Zhi        ISSN： 0529-5807


× No keyword cloud information.
  9 in total

Review 1.  Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer.

Authors:  Liangqing Ge; Ruizheng Shi
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.

Authors:  Di Ma; Zheng Wang; Lin Yang; Xinlin Mu; Yan Wang; Xinming Zhao; Junling Li; Dongmei Lin
Journal:  Oncotarget       Date:  2016-09-27

3.  [Assessment of ALK rearrangement in non-small cell lung cancer: using enhancing immunohistochemical way and fluorescence in situ hybridization].

Authors:  Hui Meng; Xianzheng Gao; Lan Zhang; Fang Liu; Wencai Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-02

Review 4.  [Diagnosis for ALK positive non-small cell lung cancer].

Authors:  Qin Feng; Xin Yang; Dongmei Lin
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-02

5.  [Clinical Significance and Mechanism of PI3K p110β Overexpression
 in Non-small Cell Lung Cancer].

Authors:  Yan Xiong; Linlin Qu; Dong Li; Ying Wang; Ting Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-12-20

6.  Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma.

Authors:  Hongyan Wang; Wen Zhang; Kai Wang; Xiaofeng Li
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

7.  Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.

Authors:  Rui-Lian Chen; Jun Zhao; Xu-Chao Zhang; Na-Na Lou; Hua-Jun Chen; Xue Yang; Jian Su; Zhi Xie; Qing Zhou; Hai-Yan Tu; Wen-Zhao Zhong; Hong-Hong Yan; Wei-Bang Guo; Yi-Long Wu; Jin-Ji Yang
Journal:  BMC Cancer       Date:  2018-11-26       Impact factor: 4.430

8.  Expression and significance of circulating microRNA-31 in lung cancer patients.

Authors:  Hai-Jun Yan; Ji-Yong Ma; Li Wang; Wei Gu
Journal:  Med Sci Monit       Date:  2015-03-09

9.  [The research of clinical pathological features of ALK positive lung cancer in 525 patients and the discussion of detection methods].

Authors:  Xiang Zhu; Hongwei Li; Baoshan Cao; Chen Liu; Li Liang; Yuxiang Wang; Jiangfeng You; Fei Gao; Xiaolong Ma; Yan Liu; Hua Wang; Yan Zhang; Jian Chen; Bo Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.